

Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/SEDC0DC1F4D3EN.html>

Date: November 2024

Pages: 70

Price: US\$ 5,950.00 (Single User License)

ID: SEDC0DC1F4D3EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Scleroderma Therapeutics Market Growth & Trends

The global scleroderma therapeutics market size is expected to reach USD 3.44 billion by 2030, registering a CAGR of 5.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.

The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company's share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.

The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting

high development costs and in reaping larger benefits from one molecule already developed and present in the market.

Scleroderma Therapeutics Market Report Highlights

The immunosuppressors segment accounted for the largest share of 27.4% in 2024, and is likely to maintain the dominance throughout the forecast years

High preference for immunosuppressants owing to the favorable reimbursement scenario associated with this drug class supports its dominant market share

Systemic scleroderma indication segment accounted for the major market share and will expand further due to use of high-priced immunosuppressants

The U.S. market accounted for 90.6% share of the North America scleroderma therapeutics market in 2024. Expected label expansions and expected launch of first-in-class therapies coupled with an evolving reimbursement landscape for orphan drugs support continual scleroderma therapeutics market growth

Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Drug Class
 - 1.2.2. Indication
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
 - 1.5.1. Purchased Database
 - 1.5.2. GVR's Internal Database
 - 1.5.3. Secondary Sources
 - 1.5.4. Primary Research
- 1.6. Information Analysis
 - 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
 - 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. SCLERODERMA THERAPEUTICS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
 - 3.3.1. Industry Analysis - Porter's Five Forces Analysis
 - 3.3.1.1. Supplier Power

- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

CHAPTER 4. SCLERODERMA THERAPEUTICS MARKET: DRUG CLASS BUSINESS ANALYSIS

- 4.1. Drug Class Market Share, 2024 & 2030
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
- 4.4. Immunosuppressors
 - 4.4.1. Immunosuppressors Market, 2018 - 2030 (USD Million)
- 4.5. Phosphodiesterase 5 inhibitors - PHA
 - 4.5.1. Phosphodiesterase 5 inhibitors - PHA Market, 2018 - 2030 (USD Million)
- 4.6. Endothelin Receptor Antagonists
 - 4.6.1. Endothelin Receptor Antagonists Market, 2018 - 2030 (USD Million)
- 4.7. Prostacyclin Analogues
 - 4.7.1. Prostacyclin Analogues Market, 2018 - 2030 (USD Million)
- 4.8. Calcium Channel Blockers
 - 4.8.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
- 4.9. Analgesics
 - 4.9.1. Analgesics Market, 2018 - 2030 (USD Million)
- 4.10. Calcium Channel Blockers
 - 4.10.1. Calcium Channel Blockers Market, 2018 - 2030 (USD Million)
- 4.11. Others
 - 4.11.1. Others Market, 2018 - 2030 (USD Million)

CHAPTER 5. SCLERODERMA THERAPEUTICS MARKET: INDICATION BUSINESS ANALYSIS

- 5.1. Indication Market Share, 2024 & 2030
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
- 5.4. Systemic Scleroderma
 - 5.4.1. Systemic Scleroderma Market, 2018 - 2030 (USD Million)

5.4.2. Morphea

5.4.2.1. Morphea Market, 2018 - 2030 (USD Million)

5.4.3. Linear

5.4.3.1. Linear Market, 2018 - 2030 (USD Million)

5.5. Localized Scleroderma

5.5.1. Localized Scleroderma Market, 2018 - 2030 (USD Million)

5.5.2. Diffuse Systemic Sclerosis

5.5.2.1. Diffuse systemic sclerosis market, 2018 - 2030 (USD Million)

5.5.3. Limited Cutaneous Systemic Sclerosis Syndrome

5.5.3.1. Limited cutaneous systemic sclerosis syndrome market, 2018 - 2030 (USD Million)

CHAPTER 6. SCLERODERMA THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS AND INDICATION

6.1. Regional Market Share Analysis, 2024 & 2030

6.2. Regional Market Dashboard

6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:

6.4. North America

6.4.1. North America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.4.2. U.S.

6.4.2.1. Key Country Dynamics

6.4.2.2. Regulatory Framework

6.4.2.3. Competitive Insights

6.4.2.4. U.S. Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.4.3. Canada

6.4.3.1. Key Country Dynamics

6.4.3.2. Regulatory Framework

6.4.3.3. Competitive Insights

6.4.3.4. Canada Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.4.4. Mexico

6.4.4.1. Key Country Dynamics

6.4.4.2. Regulatory Framework

6.4.4.3. Competitive Insights

6.4.4.4. Mexico Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5. Europe

6.5.1. Europe Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.5.2. UK

6.5.2.1. Key Country Dynamics

6.5.2.2. Regulatory Framework

6.5.2.3. Competitive Insights

6.5.2.4. UK Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.3. Germany

6.5.3.1. Key Country Dynamics

6.5.3.2. Regulatory Framework

6.5.3.3. Competitive Insights

6.5.3.4. Germany Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.4. France

6.5.4.1. Key Country Dynamics

6.5.4.2. Regulatory Framework

6.5.4.3. Competitive Insights

6.5.4.4. France Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.5. Italy

6.5.5.1. Key Country Dynamics

6.5.5.2. Regulatory Framework

6.5.5.3. Competitive Insights

6.5.5.4. Italy Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.6. Spain

6.5.6.1. Key Country Dynamics

6.5.6.2. Regulatory Framework

6.5.6.3. Competitive Insights

6.5.6.4. Spain Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.7. Denmark

6.5.7.1. Key Country Dynamics

6.5.7.2. Regulatory Framework

6.5.7.3. Competitive Insights

6.5.7.4. Denmark Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.5.8. Sweden

6.5.8.1. Key Country Dynamics

6.5.8.2. Regulatory Framework

6.5.8.3. Competitive Insights

6.5.8.4. Sweden Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.5.9. Norway

6.5.9.1. Key Country Dynamics

6.5.9.2. Regulatory Framework

6.5.9.3. Competitive Insights

6.5.9.4. Norway Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6. Asia Pacific

6.6.1. Asia Pacific Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.2. Japan

6.6.2.1. Key Country Dynamics

6.6.2.2. Regulatory Framework

6.6.2.3. Competitive Insights

6.6.2.4. Japan Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.3. China

6.6.3.1. Key Country Dynamics

6.6.3.2. Regulatory Framework

6.6.3.3. Competitive Insights

6.6.3.4. China Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.4. India

6.6.4.1. Key Country Dynamics

6.6.4.2. Regulatory Framework

6.6.4.3. Competitive Insights

6.6.4.4. India Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.5. Australia

6.6.5.1. Key Country Dynamics

6.6.5.2. Regulatory Framework

6.6.5.3. Competitive Insights

6.6.5.4. Australia Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.6. South Korea

6.6.6.1. Key Country Dynamics

6.6.6.2. Regulatory Framework

6.6.6.3. Competitive Insights

6.6.6.4. South Korea Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.6.7. Thailand

6.6.7.1. Key Country Dynamics

6.6.7.2. Regulatory Framework

6.6.7.3. Competitive Insights

6.6.7.4. Thailand Scleroderma therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.7. Latin America

6.7.1. Latin America Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.7.2. Brazil

6.7.2.1. Key Country Dynamics

6.7.2.2. Regulatory Framework

6.7.2.3. Competitive Insights

6.7.2.4. Brazil Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.7.3. Argentina

6.7.3.1. Key Country Dynamics

6.7.3.2. Regulatory Framework

6.7.3.3. Competitive Insights

6.7.3.4. Argentina Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8. MEA

6.8.1. MEA Scleroderma Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)

6.8.2. South Africa

6.8.2.1. Key Country Dynamics

6.8.2.2. Regulatory Framework

6.8.2.3. Competitive Insights

6.8.2.4. South Africa Scleroderma Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

6.8.3. Saudi Arabia

6.8.3.1. Key Country Dynamics

6.8.3.2. Regulatory Framework

6.8.3.3. Competitive Insights

6.8.3.4. Saudi Arabia Scleroderma Therapeutics Market Estimates And Forecasts,
2018 - 2030 (USD Million)

6.8.4. UAE

6.8.4.1. Key Country Dynamics

6.8.4.2. Regulatory Framework

6.8.4.3. Competitive Insights

6.8.4.4. UAE Scleroderma Therapeutics Market Estimates And Forecasts, 2018 -
2030 (USD Million)

6.8.5. Kuwait

6.8.5.1. Key Country Dynamics

6.8.5.2. Regulatory Framework

6.8.5.3. Competitive Insights

6.8.5.4. Kuwait Scleroderma Therapeutics Market Estimates And Forecasts, 2018 -
2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Participant Overview

7.2. Company Market Position Analysis

7.3. Company Categorization

7.4. Strategy Mapping

7.5. Company Profiles/Listing

7.5.1. F. Hoffman La-Roche Ltd

7.5.1.1. Overview

7.5.1.2. Financial Performance

7.5.1.3. Product Benchmarking

7.5.1.4. Strategic Initiatives

7.5.2. Bristol-Myers Squibb Company

7.5.2.1. Overview

7.5.2.2. Financial Performance

7.5.2.3. Product Benchmarking

7.5.2.4. Strategic Initiatives

7.5.3. Bayer AG

7.5.3.1. Overview

7.5.3.2. Financial Performance

7.5.3.3. Product Benchmarking

7.5.3.4. Strategic Initiatives

7.5.4. Boehringer Ingelheim International GmbH

- 7.5.4.1. Overview
- 7.5.4.2. Financial Performance
- 7.5.4.3. Product Benchmarking
- 7.5.4.4. Strategic Initiatives
- 7.5.5. Emerald Health Pharmaceuticals
 - 7.5.5.1. Overview
 - 7.5.5.2. Financial Performance
 - 7.5.5.3. Product Benchmarking
 - 7.5.5.4. Strategic Initiatives
- 7.5.6. Sanofi
 - 7.5.6.1. Overview
 - 7.5.6.2. Financial Performance
 - 7.5.6.3. Product Benchmarking
 - 7.5.6.4. Strategic Initiatives
- 7.5.7. Cytori Therapeutics Inc.
 - 7.5.7.1. Overview
 - 7.5.7.2. Financial Performance
 - 7.5.7.3. Product Benchmarking
 - 7.5.7.4. Strategic Initiatives
- 7.5.8. Chemomab
 - 7.5.8.1. Overview
 - 7.5.8.2. Financial Performance
 - 7.5.8.3. Product Benchmarking
 - 7.5.8.4. Strategic Initiatives
- 7.5.9. Corbus Pharmaceuticals Holdings, Inc.
 - 7.5.9.1. Overview
 - 7.5.9.2. Financial Performance
 - 7.5.9.3. Product Benchmarking
 - 7.5.9.4. Strategic Initiatives
- 7.5.10. Calliditas Therapeutics AB
 - 7.5.10.1. Overview
 - 7.5.10.2. Financial Performance
 - 7.5.10.3. Product Benchmarking
 - 7.5.10.4. Strategic Initiatives

I would like to order

Product name: Scleroderma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Immunosuppressors, ERA, CCBs, PA), By Indication (Systemic, Localized), By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/SEDC0DC1F4D3EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SEDC0DC1F4D3EN.html>